Back to YC Companies

    Evolvere BioSciences

    Summer 2024
    Active

    Making Next-Generation Antibiotics that Outpace Bacterial Evolution

    3 people View on YC

    Evolvere BioSciences at a glance

    Y Combinator batch
    Summer 2024
    Status
    Active
    Industry
    Healthcare
    Team size
    3 people
    Location
    Not recorded
    Website
    Not recorded

    Every field above comes from the Y Combinator company record. Nothing is estimated.

    Compare Evolvere BioSciences with similar YC companies →

    About Evolvere BioSciences

    🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.

    Tags:
    AI-powered Drug Discovery
    Biotech
    Therapeutics
    AI
    Biotechnology